Skip to content
PIPR

Piper Sandler Companies

Piper Sandler Companies Q1 FY2026 earnings call

May 1, 2026 · fiscal period ended 2026-03

EPS · actual vs est

$1.00 / $0.85Beat +17.6%

Revenue · actual vs est

$474.4M / $436.8MBeat +8.6%
Ask about this call

Summary

Generated 2026-05-01

Management highlights

• Chad mentioned strong start to the year with adjusted net revenues of $470M, 10th consecutive quarter of y-o-y growth, 20% operating margin, and adjusted EPS of $1. Corporate investment banking had first quarter record revenues of $324M (up 30% y-o-y). Healthcare franchise set new revenue high. Financial services group ranked number one in U.S. bank M&A by deal value. Advisory revenues were first quarter record of $251M (up 16% y-o-y). Ranked 2nd in USM&A for deals under $2B and 3rd under $5B. Debt capital markets and private capital advisory showing positive momentum. • Deb discussed public finance business with $24M municipal financing revenues (down 9% y-o-y), 98 municipal negotiated transactions underwritten, $3B par value raised. Equity brokerage had record revenues of $60M (up 11% y-o-y) due to higher volatility. Fixed income business had $50M revenues (up 6% y-o-y) but impacted by March volatility. • Kate reviewed financial results: net revenues $470M, up 22% y-o-y. Operating income grew 37% y-o-y. Compensation ratio 61.6% (improvement of 90 basis points). Non-compensation expenses $86M (up 15% y-o-y, including $8.5M litigation-related expense). Income tax expense reduced by $7M tax benefits. Returned $171M to shareholders including dividends and share repurchases. Board approved 14% increase in quarterly cash dividend.

View in transcript ↓

Segment performance

First quarter adjusted net revenues were $470 million. Corporate investment banking had revenues of $324 million (up 30% y-o-y). Healthcare franchise had strong revenues, with med tech and biopharma teams driving growth, and ranked top advisor in U.S. MedTech M&A by number of announced deals. Financial services group had strong quarter with bank M&A transactions, ranking number one advisor in U.S. bank M&A by deal value. Advisory revenues were a first quarter record of $251 million (up 16% y-o-y), ranked 2nd in USM&A for deals under $2B and 3rd under $5B. Debt capital markets advisory had strong start. Private capital advisory group showing positive momentum. Public finance business had $24M municipal financing revenues (down 9% y-o-y). Equity brokerage had record first quarter revenues of $60M (up 11% y-o-y) due to higher volatility. Fixed income business had $50M revenues (up 6% y-o-y) but impacted by March volatility.

View in transcript ↓

Guidance

• Expect second quarter advisory revenues to be similar to first quarter. • Expect second quarter corporate financing revenues to decline from strong first quarter. • Anticipate second quarter public finance revenues to improve modestly from first quarter. • Expect second quarter equity brokerage revenues to decline from record first quarter levels. • Margin expansion remains a strategic priority as they continue to scale the platform.

View in transcript ↓

Risks

• Near-term macroeconomic environment remains uncertain. • Volatility in fixed income business negatively impacted regular-weight client activity in March. • Uncertainty regarding the timing of transactions influenced by market conditions. • Impact of litigation-related expense ($8.5M) in the quarter. • Potential impact of geopolitical events on trading volumes and fixed income business. • Slow start to second quarter fixed income business due to ongoing geopolitical developments keeping clients on the sidelines.

View in transcript ↓

Q&A highlights

Q: Update on bank M&A activity and rate vol impact on hedging business.

A: Announced Bank M&A a little slower than anticipated, but decent volume on smaller transactions. Derivatives desk busy with hedging conversations but volatility makes it challenging to determine positioning.

Q: Equity capital markets activity sustainability, especially healthcare.

A: Good quarter for market and Piper Sandler, but first quarter market share not sustainable, but market remains open and biotech market trades differently.

Q: Advisory outlook, sectors with slowdown, backlog visibility.

A: Advisory fees expected to be down sequentially. Impact varies by sector, with banks and sponsor activity having some impact, but no real panic, market fine but not accelerating.

Q: Software M&A outlook amidst AI disruption.

A: Technology is an area of investment, impacted relatively less historically, but slower, cautious outlook due to valuations and AI shifts.

Q: Non-M&A contribution and outlook.

A: Non-M&A had good Q1 with debt capital markets advisory being a bright spot, private capital advisory showing progress across industry teams.

Q: Fixed income revenues, moving parts.

A: Resilient due to balance sheet restructuring trades with bank closings, but 2Q started slowly due to volatility and geopolitical environment.

Q: Comp ratio outlook.

A: Now consistently at low end of guided range (61.5-62.5), pleased with progress, but comp model variable, balance between leverage and additive investment opportunities.

Q: Advisory pipeline winter to spring activity.

A: Q1 always challenge, strong Q4 impacted Q1 pace, commentary on similar Q2 advisory due to Q1 and Q4 combination.

Q: What markets need to see for upward slope.

A: Difficult to pinpoint, but stability in various segments like energy, stock prices, and sponsor certainty of close needed.

View in transcript ↓

Key numbers

Reported versus consensus

Earnings calendar feed

MetricReportedConsensusDeltaPrior year
EPS$1.00$0.85+17.6%$4.09
Revenue$474.4M$436.8M+8.6%$357.3M

Transcript

May 1, 2026

Full transcript unavailable for redistribution

The structured summary above covers the available call sections. Full transcript text is not included on this page.

Continue exploring

Prior quarters

This page presents the stored structured earnings-call summary and deterministic earnings calendar values. How this is generated. For informational purposes only; not investment advice.